Octavus Consulting- Evidence-Based Consulting Services.

Call us: +91 120 428 0707

Email us: bd@octavusconsulting.com

Contact Us
Contact Us

Animal Health 2025 | Market Trends & Innovations Explained – Octavus Insights Corner

Insights Details

Month: Oct 25

Tags: Animal Health, Conference, Pre-clinical, Phase 1, Phase 2, Phase 3, US FDA, Europe, Company Profile, Product profile, Deal Analysis, Funding Analysis, Landscape, Livestock Animals, Companion Animals, Top Diseases, Grooming & Smart Health Monitoring Device, Economic Impact, Emerging Technology, Artificial Intelligence, Digital Technology, Policy, USA, Veterinary Clinical Trials, Global Market Size, Clinical trials

Let’s Work Together for Development

Call us directly, submit a sample or email us!

Business Address
First Floor, B-66, Sector 63,
Noida, UP, India-201301
Connect With Us
Call us: +91 120 428 0707
bd@octavusconsulting.com
Working Hours
Mon - Fri: 10.00 AM - 07.00 PM
Holidays : Closed
Get in Touch With Us

About topic:

How the global animal health industry is evolving across prevention, treatment, and digital technologies, and highlights key numbers, regulations, products, and companies shaping the space in 2024–2028. It also contrasts mature markets like the US with India’s livestock‑driven structure and shows how AI, wearables, and telemedicine are becoming core to veterinary care

Animal Health 2025 | Market Trends & Innovations Explained – Octavus Insights Corner

Highlights:

Global animal health is a large and growing market (about 63 billion dollars in 2024, projected to the mid 80 billion dollar range by 2028), with Zoetis as the leading company (2024 revenue above 9 billion dollars, roughly two thirds from companion animals), and key players such as Merck Animal Health, Boehringer Ingelheim, and others; India has just over 3% share with a livestock driven, fast growing market expected to reach around 1.9 billion dollars by 2030
Top earning products are dominated by parasiticide and dermatology brands, especially Simparica Trio and other Zoetis lines (Apoquel, Revolution family) and NexGard from Boehringer Ingelheim, which is a leading chewable flea and tick medicine for dogs with rising sales
Innovation is visible in roughly 100+ ongoing canine veterinary clinical trials (with oncology and internal medicine leading, and additional trials in feline, equine, and wildlife species), supporting a robust pipeline behind these blockbuster products and future market growth
There is strong opportunity across the value chain: deals and roll ups of clinics/hospitals, tech and data partnerships, and specialized consulting offerings (market sizing, primary research, competitive intelligence, product testing, conference driven insights) for companies looking to expand or reposition in the animal health sector
Get in Touch With Us
PREVIOUS PROJECT
NEXT PROJECT